欧美日本一道本一区二区_亚洲免费影视_91手机在线看片_精品欧美成人高清在线观看_少妇作爱bbbb免费看_51久久夜色精品国产水果派解说

美國Invitrogen CellzDirect    
全球生命技術行業的領導者Invitrogen(英杰生命技術有限公司)新近成功收購了CellzDirect Inc (CellzDirect公司)。這是繼去年成功收購Cascade Biologics之后，Invitrogen在細胞生物學領域的又一個重大舉措。

CellzDirect是一家私有的生物技術公司，成立于2001年，總部位于美國北卡羅林那州的德罕市(Durham, North Carolina, USA)，向生物公司和制藥公司提供高品質的細胞產品和服務，主要關注的領域包括藥物代謝，藥物交互作用和藥物轉運體等。在CellzDirect的支持下，科學家們可以更好的開展科研工作，加速安全、高效藥品的研發。

Hepatocyte(人肝細胞)是CellzDirect的主要產品之一，它是新藥檢測的重要工具。原代hepatocyte能夠預測各組分在肝中對酶代謝的影響，是現今該領域最受關注的工具，也是FDA要求使用的檢測方法，它可以大大降低臨床試驗失敗造成的巨大損失。因此，CellzDirect的產品主要用于生物和制藥公司的研發。原代hepatocyte也可用于生物醫療，用來研究肝的疾病，和細胞功能的下游價值，因為體內的每一個系統都與肝密切相關。

CellzDirect自成立以來，以其獨特而又健康的組織來源網絡，高品質hepatocyte的制備，雄厚的檢測平臺，和出色的結果分析，取得了飛速的發展，平均每年以70%的速度上升。由于CellzDirect在科學界的領導地位，與科學和工業領域權威的磋商，和持續不斷的與醫療團體、制定規章的機構和其用戶的溝通，使其在原代細胞的供應者中一枝獨秀。

CellzDirect的加盟，無疑會大大推進Invitrogen在生命技術行業，特別是在細胞生物學領域的領導地位。對于原旗下的GIBCO?品牌——這一全球細胞培養領域的泰斗，CellzDirect是其非常有益的補充和促進。CellzDirect高價值的產品和服務，進一步將Invitrogen細胞系統的產品線完善和升值，至此，Invitrogen已擁有了完整的、高品質的細胞系統的產品線，包括原代細胞，培養基，三維基質，生長因子，等等。
 CellzDirect is building a preeminent cell-based bioscience company that provides innovative ADME products and services to expedite the development of safe, effective drugs.

Our Company

Now part of the Invitrogen family, CellzDirect provides high-quality in vitro ADME cell products and contract laboratory and consulting services focused primarily on drug metabolism and transport. Our clients include leaders in the pharmaceutical, biotech, academic, chemical and consumer products fields as well as government agencies. With CellzDirect’s support, scientists conduct research that accelerates the discovery of safe and effective drugs.

CellzDirect offers a complete line of fresh and cryopreserved hepatocytes and liver subcellular fractions, and transporters derived from a variety of species, including human, non-human primate, dog, rat and mouse. Members of our scientific staff have dedicated up to 20 years on research to optimize the isolation conditions and culture techniques by species.

Our service offerings include drug-drug interaction studies, drug metabolism studies and hepatotoxicity studies, such as enzyme induction and inhibition, reaction phenotyping, metabolite stability and profiling, and P-gp assays. These studies can be conducted in GLP (Good Laboratory Practices) or non-GLP formats, and study data can be presented for FDA submissions.